145 related articles for article (PubMed ID: 31838284)
21. Profiling and characterization of sialylated N-glycans by 2D-HPLC (HIAX/PGC) with online orbitrap MS/MS and offline MSn.
Hanneman AJ; Strand J; Huang CT
J Pharm Sci; 2014 Feb; 103(2):400-8. PubMed ID: 24302562
[TBL] [Abstract][Full Text] [Related]
22. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
23. Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs.
Grampp G; McElroy PL; Camblin G; Pollock A
J Pharm Sci; 2018 Jun; 107(6):1512-1520. PubMed ID: 29408510
[TBL] [Abstract][Full Text] [Related]
24. Epoetin biosimilars in Europe: five years on.
Mikhail A; Farouk M
Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
[TBL] [Abstract][Full Text] [Related]
25. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.
Deicher R; Hörl WH
Drugs; 2004; 64(5):499-509. PubMed ID: 14977387
[TBL] [Abstract][Full Text] [Related]
26. Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo).
Llop E; Gutiérrez-Gallego R; Segura J; Mallorquí J; Pascual JA
Anal Biochem; 2008 Dec; 383(2):243-54. PubMed ID: 18804089
[TBL] [Abstract][Full Text] [Related]
27. Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.
Duh MS; Weiner JR; White LA; Lefebvre P; Greenberg PE
Pharmacoeconomics; 2008; 26(2):99-120. PubMed ID: 18198931
[TBL] [Abstract][Full Text] [Related]
28. Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
Tani J; Ito Y; Tatemichi S; Yamakami M; Fukui T; Hatano Y; Kakimoto S; Kotani A; Sugimura A; Mihara K; Yamamoto R; Tanaka N; Minami K; Takahashi K; Hirato T
PLoS One; 2020; 15(4):e0231830. PubMed ID: 32302352
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin produced in a human cell line (Dynepo) has significant differences in glycosylation compared with erythropoietins produced in CHO cell lines.
Shahrokh Z; Royle L; Saldova R; Bones J; Abrahams JL; Artemenko NV; Flatman S; Davies M; Baycroft A; Sehgal S; Heartlein MW; Harvey DJ; Rudd PM
Mol Pharm; 2011 Feb; 8(1):286-96. PubMed ID: 21138277
[TBL] [Abstract][Full Text] [Related]
30. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.
Muller RJ; Baribeault D
Am J Health Syst Pharm; 2007 Dec; 64(24):2547-56. PubMed ID: 18056942
[TBL] [Abstract][Full Text] [Related]
31. Structural analysis of the sialylated N- and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetyllactosamine units.
Hokke CH; Bergwerff AA; Van Dedem GW; Kamerling JP; Vliegenthart JF
Eur J Biochem; 1995 Mar; 228(3):981-1008. PubMed ID: 7737204
[TBL] [Abstract][Full Text] [Related]
32. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
33. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z; DeSantis ER
Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
[TBL] [Abstract][Full Text] [Related]
34. An Integrated Strategy Reveals Complex Glycosylation of Erythropoietin Using Mass Spectrometry.
Guan Y; Zhang M; Gaikwad M; Voss H; Fazel R; Ansari S; Shen H; Wang J; Schlüter H
J Proteome Res; 2021 Jul; 20(7):3654-3663. PubMed ID: 34110173
[TBL] [Abstract][Full Text] [Related]
35. Sensitive and comprehensive analysis of O-glycosylation in biotherapeutics: a case study of novel erythropoiesis stimulating protein.
Kim U; Oh MJ; Seo Y; Jeon Y; Eom JH; An HJ
Bioanalysis; 2017 Sep; 9(18):1373-1383. PubMed ID: 28920453
[TBL] [Abstract][Full Text] [Related]
36. Assessment of methods for determination of glycan composition of erythropoietin.
Cowper B; Burns C; Bristow AF; Letallec D; Costanzo A
Pharmeur Bio Sci Notes; 2019; 2019():34-53. PubMed ID: 31767053
[TBL] [Abstract][Full Text] [Related]
37. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
Biggar P; Ketteler M; Hennemann H; Dömling R
Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
[TBL] [Abstract][Full Text] [Related]
38. High-resolution glycoform profiling of intact therapeutic proteins by hydrophilic interaction chromatography-mass spectrometry.
Domínguez-Vega E; Tengattini S; Peintner C; van Angeren J; Temporini C; Haselberg R; Massolini G; Somsen GW
Talanta; 2018 Jul; 184():375-381. PubMed ID: 29674057
[TBL] [Abstract][Full Text] [Related]
39. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact.
Kiss Z; Elliott S; Jedynasty K; Tesar V; Szegedi J
Eur J Clin Pharmacol; 2010 Apr; 66(4):331-40. PubMed ID: 20127232
[TBL] [Abstract][Full Text] [Related]
40. Erythropoietin and erythropoiesis stimulating agents.
Debeljak N; Sytkowski AJ
Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
